Main
cancers
MUTANT, CANCERS
BRAFImmune checkpoint blockade (ICB), particularly agents that block the programmed death (PD)-1 pathway, has revolutionized the treatment of many cancers with the potential for long-term durable responsesInterestingly, ~15–20% of BRAFPreclinical models suggest that combining MAPK inhibition and ICB could enhance antitumor efficacy in BRAF and KRAS mutant cancersBased on these observations, we investigated the potential cooperativity of BRAF/MAPK pathway inhibition and ICB in BRAF